心血管疾病：质量调整生命年的代价——他汀类药物在慢性肾脏病中的成本效益 - Suppr

Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.

作者信息

Jha Vivekanand, Modi Gopesh K

机构信息

George Institute for Global Health, 219-221, Spelndor Forum, Jasola, New Delhi 110 025, India.

出版信息

Nat Rev Nephrol. 2013 Jul;9(7):377-9. doi: 10.1038/nrneph.2013.104. Epub 2013 Jun 4.

DOI:10.1038/nrneph.2013.104

PMID:23732458

Abstract

摘要

相似文献

Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.

Nat Rev Nephrol. 2013 Jul;9(7):377-9. doi: 10.1038/nrneph.2013.104. Epub 2013 Jun 4.

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.

J Am Coll Cardiol. 2013 Mar 26;61(12):1250-8. doi: 10.1016/j.jacc.2012.12.034.

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.

Eur Heart J. 2014 Feb;35(5):290-8. doi: 10.1093/eurheartj/eht232. Epub 2013 Jul 9.

Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?

Br J Gen Pract. 2010 Jan;60(570):50-2. doi: 10.3399/bjgp10X482112.

Pravastatin and coronary heart disease.

N Engl J Med. 1999 Apr 8;340(14):1116-7.

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.

Ann Intern Med. 2000 May 16;132(10):780-7. doi: 10.7326/0003-4819-132-10-200005160-00003.

Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.

Cardiovasc Drugs Ther. 2015 Apr;29(2):187-97. doi: 10.1007/s10557-015-6584-7.

Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?

Circulation. 2010 Oct 12;122(15):1446-8. doi: 10.1161/CIRCULATIONAHA.110.981944. Epub 2010 Sep 27.

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Circulation. 2007 May 8;115(18):2398-409. doi: 10.1161/CIRCULATIONAHA.106.667683. Epub 2007 Apr 23.

[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].

Herz. 2000 Aug;25(5):487-94. doi: 10.1007/pl00001961.

引用本文的文献

Outcome of live and deceased donor renal transplantation in patients aged ≥55 years: A single-center experience.

Indian J Nephrol. 2014 Jan;24(1):9-14. doi: 10.4103/0971-4065.125049.

Epidemiology of dyslipidemia in chronic kidney disease.

Clin Exp Nephrol. 2014 Apr;18(2):185-8. doi: 10.1007/s10157-013-0891-8. Epub 2014 Jan 11.

本文引用的文献

Chronic kidney disease: global dimension and perspectives.

Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

BMJ. 2013 Mar 25;346:f1049. doi: 10.1136/bmj.f1049.

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.

J Am Coll Cardiol. 2013 Mar 26;61(12):1250-8. doi: 10.1016/j.jacc.2012.12.034.

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Lancet. 2012 Sep 1;380(9844):807-14. doi: 10.1016/S0140-6736(12)60572-8. Epub 2012 Jun 19.

'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States.

Am J Kidney Dis. 2012 Jan;59(1 Suppl 1):A7, e1-420. doi: 10.1053/j.ajkd.2011.11.015.

Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.

Circulation. 2011 Jul 12;124(2):146-53. doi: 10.1161/CIRCULATIONAHA.110.986349. Epub 2011 Jun 27.

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Lancet. 2010 Jun 12;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5. Epub 2010 May 17.

Accounting for the missing opportunity costs in incremental cost-outcome analysis.

Appl Health Econ Health Policy. 2002;1(4):191-6.

Incorporating societal concerns for fairness in numerical valuations of health programmes.

Health Econ. 1999 Feb;8(1):25-39. doi: 10.1002/(sici)1099-1050(199902)8:1<25::aid-hec398>3.0.co;2-h.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献